AMRN Share Price

Open 4.11 Change Price %
High 4.14 1 Day -0.15 -3.66
Low 3.91 1 Week -0.21 -5.05
Close 3.95 1 Month 0.17 4.50
Volume 1993324 1 Year 1.56 65.27
52 Week High 4.47
52 Week Low 2.37
AMRN Important Levels
Resistance 2 4.16
Resistance 1 4.08
Pivot 4.00
Support 1 3.82
Support 2 3.74
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
QQQ 143.96 -0.63%
SIRI 5.83 8.16%
FB 170.44 2.92%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SHOR 7.50 28.21%
OPNT 14.53 27.46%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
LPSN 13.50 18.42%
TREE 217.15 18.14%
AXTI 8.80 15.79%
DRYS 1.20 15.38%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
IPCI 1.36 -45.38%
DVOX 0.05 -44.44%
GLCH 0.70 -44.00%
PRXI 0.21 -43.24%
More..

Amarin Corporation PLC (NASDAQ: AMRN)

AMRN Technical Analysis 4
As on 27th Jul 2017 AMRN Share Price closed @ 3.95 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 3.21 & Buy for SHORT-TERM with Stoploss of 3.45 we also expect STOCK to react on Following IMPORTANT LEVELS.
AMRN Target for July
1st Target up-side 4.67
2nd Target up-side 5.12
3rd Target up-side 5.57
1st Target down-side 3.39
2nd Target down-side 2.94
3rd Target down-side 2.49
AMRN Other Details
Segment EQ
Market Capital 1595353216.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.amarincorp.com
AMRN Address
AMRN
2 Pembroke House
Upper Pembroke Street 28-32
Dublin, 2
Ireland
Phone: 353 1 669 9020
AMRN Latest News
Interactive Technical Analysis Chart Amarin Corporation PLC ( AMRN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Amarin Corporation PLC
AMRN Business Profile
Amarin Corporation plc (Amarin), incorporated on March 1, 1989, is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company’s product candidate is AMR101, an ultra-pure omega-3 fatty acid. It is developing AMR101 for the treatment of patients with high triglyceride levels, or hypertriglyceridemia. In September 2011, it filed a New Drug Application (NDA), with the United States Food and Drug Administration (FDA). In December 2011, it commenced patient dosing in its cardiovascular outcomes study of AMR101, titled REDUCE-IT (Reduction of Cardiovascular Events with eicosapentanoic acid (EPA) - Intervention Trial). The MARINE trial is conducted with omega-3 fatty acids in treating patients with very high triglycerides, is a Phase-III, multi-center, placebo-controlled, randomized, double-blind, 12-week study. Patients enrolled in the MARINE trial were given the option to be treated with AMR101 for a period of up to 40-weeks after their last dose in the pivotal trial. The ANCHOR trial is a multi-center, placebo-controlled, randomized, double-blind, 12-week pivotal study in patients with high triglycerides who were on optimized statin therapy. In April 2011, it reported top-line results from the ANCHOR trial. Prior to commencing the MARINE and ANCHOR trials, it conducted a pre-clinical program for AMR101, including toxicology and pharmacology studies. In addition to the MARINE and ANCHOR trials, it completed a 28-day pharmacokinetic study. It is also focusing development of other compounds based on its internal lipid science expertise.